for the GUSTO Investigators* Background A paradoxical increased risk of death has been reported during the first 24 hours after thrombolysis for myocardial infarction. The mechanism of this phenomenon is not known, nor is its relation to the success or failure of reperfusion. The present study was a prospectively designed analysis of deaths occurring within the first 24 hours in the GUSTO trial.
Background A paradoxical increased risk of death has been reported during the first 24 hours after thrombolysis for myocardial infarction. The mechanism of this phenomenon is not known, nor is its relation to the success or failure of reperfusion. The present study was a prospectively designed analysis of deaths occurring within the first 24 hours in the GUSTO trial.
Methods and Results There were 41 021 patients enrolled in GUSTO, a randomized comparison of streptokinase with intravenous or subcutaneous heparin, accelerated tissue-type plasminogen activator (TPA), and combination of streptokinase and TPA. An angiographic mechanistic substudy examined reperfusion (using the TIMI flow grading criteria) 90 minutes after the assigned thrombolytic regimen was begun in 1567 patients. There were 1125 deaths (2.8%) within 24 hours ("early deaths") and 1726 additional deaths (4.2%) after 24 hours but within 30 days ("later deaths"). At the time of presentation, the most potent predictors of early death were hypotension and sinus tachycardia. In a multiple logistic regression model, lower systolic blood pressure, shorter height, higher heart rate, and the absence of prior smoking distinguished early death from later death. Reinfarction occurred in 26 patients (2.4%), shock in 572 patients (52%), atrioventricular block in 308 patients (28%), and tamponade in 106 patients (10%) dying early compared with 262 (15%), 788 (46%), 396 (23%), and 74 (4%) respective patients dying later. There were no differences in early mortality among the lacebo-controlled studies of thrombolytic therapy have demonstrated a reduction in mortality after acute myocardial infarction. [2] [3] [4] This survival benefit may be partially offset by a paradoxical increase in the risk of death during the first 24 hours after thrombolytic therapy is begun.5'6 Nearly half of the deaths among patients receiving thrombolytic drugs occur during this period.5-9 As further advances are made in reperfusion strategies, incremental mortality reductions will require that the mechanisms of death thrombolytic regimens for the first 6 hours after randomization. By 24 hours, however, mortality was 2.89% for streptokinase recipients, 2.84% for combination therapy recipients, and 2.36% for accelerated TPA recipients (P=.005). There was little difference among patients with differing flow grades in the infarct artery during the first 4 hours, although mortality among patients with grade 2 flow was initially higher. After the fourth hour, there were very few additional deaths during the first day in patients with grade 3 flow. At 24 hours, mortality was 2.35% for patients with flow grade 0 or 1, 2.92% for patients with flow grade 2, and 0.89% for patients with flow grade 3.
Conclusions Even with aggressive management regimens, mortality within the first 24 hours accounted for a large proportion of postthrombolytic deaths. Patients dying early were more likely to present with pump failure than were those dying later and were more likely to die of events related to left ventricular dysfunction, although cardiac tamponade also accounted for a significant minority of these deaths. Thus, the severity of the clinical presentation rather than the underlying risk factors predicts early mortality. Based on the angiographic substudy data, it appears that rather than hastening early mortality, successful restoration of complete antegrade flow in the infarct-related artery protects against early death. (Circulation. 1994;90:2658-2665.)
Key Words * thrombolysis * infarction * reperfusion a mortality * tamponade during this period be elucidated. Whether these deaths result from myocardial necrosis already present at the time of clinical presentation, rupture, increased bleeding, reperfusion-induced injury, or failure to restore antegrade flow in the infarct-related artery is of critical importance in designing new therapeutic strategies. Prior studies have been unable to address these questions due to either a lack of angiographic data or a limited sample size. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial afforded a unique opportunity to examine the relation between reperfusion and early mortality because it consisted of randomly assigned groups of patients in whom differing rates of early reperfusion were documented and had adequate statistical power to assess differences in early mortality.1'10 Accordingly, the present study was prospectively designed to test the hypothesis that aggressive thrombolysis would lower mortality at 24 hours.
Methods

Study Design and Data Collection
The methods and results of GUSTO have been published.1
Briefly, 41 021 patients with ST-segment elevation on the presenting ECG within 6 hours of symptom onset were randomly assigned to receive treatment with 1.5 million U streptokinase (SK) (Kabikinase) with 12 500 U heparin SC every 12 hours; 1.5 million U streptokinase with 5000-U heparin bolus IV followed by 1000 U/h; accelerated tissue patients dying early were placed on mechanical ventilators, and 256 (23%) had temporary pacemakers inserted. Cardioversion or defibrillation was performed in 485 (44%).
Coronary angiography was performed in 112 patients (10%) dying early, and percutaneous transluminal coronary angioplasty and coronary artery bypass graft surgery were performed considerably less frequently. In 34 patients, the angiogram was required by the angiographic substudy protocol, whereas in 78 it was performed at physician discretion. Of the 78 patients (7%) undergoing angiograms not mandated by the angiographic substudy, data regarding patency of the infarctrelated artery were available in 58 (74%). In these 58 patients, the investigators reported that 4 (7%) had TIMI grade 2 flow and 3 (5%) had TIMI grade 3 flow, whereas the artery was reported to be "patent" (actual Among the 2127 24-hour survivors in whom nonprotocol-mandated angiograms were done during the first day, data regarding patency were available in 1527 patients (72%). TIMI grades 2 and 3 flow were reported in 296 (19%) and 431 (28%) of these 1527 patients, respectively, whereas the artery was reported to be "patent" in an additional 77 patients (5%).
Early Mortality, Thrombolytic Treatment Assignment, and Patency  Fig 1 shows the timing of mortality according to the thrombolytic regimen assigned. There were no differences in 24-hour mortality among the SK-treated groups (SK with intravenous heparin, 2.94%; with subcutaneous heparin, 2.85%; P=.693); therefore, they are combined in this analysis. There was very little difference in early mortality among patients receiving the assigned thrombolytic regimens until the sixth hour, when the curves began to diverge. From this point on, mortality progressed at a slower rate in the accelerated TPA-treated patients. Odds ratios and confidence limits for mortality according to treatment are shown in Fig  2. As shown in Table 6 , patients dying within the first 6 hours were more likely to have diabetes, previous angina, or prior myocardial infarction and were more likely at the time of clinical presentation to be either hypotensive or in cardiogenic shock than were those dying between hours 6 and 24. Stroke-related mortality (Fig lb) accounted for very few early deaths in any of the treatment groups. In Fig 3, early mortality according to patency status is shown among patients enrolled in the angiographic substudy and assigned to undergo a protocol-directed angiogram 90 minutes after beginning thrombolytic therapy. There was little difference among patients with differing flow grades in the infarct artery during the first 4 hours, although mortality among patients with grade 2 flow was initially higher. However, after the fourth hour, there were very few additional deaths during the first day in patients with grade 3 flow. At 24 hours, mortality in this group was approximately one fourth of that in patients with grade 0, 1, or 2 flow.
Discussion
Even with modern aggressive reperfusion strategies, mortality during the early hours following acute myocardial infarction accounts for more than one third of the postinfarction deaths, but it is reduced by the restoration of antegrade blood flow in the infarctrelated artery. Our data show that rather than being responsible for an "early hazard," early reperfusion appears to protect against it. This principle is consistent with the finding that, as a rule, myocardial infarctions in this study were 3 flow also suggests that the pump failure responsible for most of the early deaths is a consequence of myocardial ischemia rather than preexisting necrosis. Accordingly, the time to beginning thrombolytic therapy was only marginally greater in patients who died early, and the proportion with a prior infarction was also only slightly higher. The finding that early mortality is lower rather than higher for patients with early grade 3 flow and for those assigned to treatment with accelerated TPA also indicates strongly that reperfusion-induced Time from Randomization (hours) patients undergoing autopsy were secondary to rupture of the ventricle.12 However, in that study of early intravenous fl-blocker therapy, it is likely that the frequency of fatal rupture would be increased because patients with incipient heart failure would be less likely to be enrolled, thus decreasing the proportion of patients likely to die of early severe pump failure. In the second phase of the TIMI II study,7 the majority of deaths during the first 18 hours after therapy was begun with accelerated TPA were due to pump failure, whereas the incidence of fatal cardiac rupture during the first 18 hours after therapy was 16%. However, among the 50% of patients in that study who underwent autopsy, evidence of rupture was found in 25%, whereas it was judged to be present in 3% of patients in whom an autopsy was not performed.8 It thus is likely that a modest proportion of early deaths in GUSTO was caused by myocardial rupture. Pathological study of ventricles in which rupture has occurred often demonstrates intramyocardial hemorrhage surrounding the rupture tract. Hemorrhage into the myocardium has also been reported to be more common in patients who have received thrombolytic therapy, 13 and it has been hypothesized that intramyocardial hemorrhage predisposes patients to rupture of the heart.14 At least one report has suggested that patients in whom rupture occurs may have a stuttering course. 15 It is possible that thrombolytic therapy hastens this progression by dissolving the thrombus that temporarily seals the rupture site, by facilitating the dissection by blood along necrotic tissue planes, or by allowing recovery of myocardial contractility, thus increasing the shear forces that lead to disruption of the myocardium. did not receive thrombolytics, these possibilities remain speculative.
What is more puzzling is the similarity in mortality for the treatment regimens and for the TIMI flow grades during the first 6 hours after treatment was begun. The median time required for reperfusion to occur following treatment with both SK and accelerated TPA has previously been reported to be slightly less than 1 hour.11,16 In addition, a small number of patients in GUSTO died before thrombolytic therapy could be begun. Thus, it would be unlikely for differences in mortality to be seen during and shortly after the first hour. The time period extending up to the sixth hour may represent the time required for sufficient recovery of ventricular muscle function after ischemia ("stunning")17 to prevent or reverse pump failure, or it may represent a period during which a detrimental effect of reperfusion is balanced by the benefit of reperfusion. As an alternative, "reperfusion dysrhythmias"'18 during this extremely early period may be responsible for a number of deaths. In the TIMI II experience, the frequency of lethal dysrhythmias did not differ between patients dying within 4 hours and those dying between 4 and 18 hours; however, in that study, there were small numbers of patients in each of the two groups.5 In the present study, however, there was more evidence of both severe pump dysfunction at the time of clinical presentation and of preexisting cardiovascular disease (Table 6 ) in those patients who died within the first 6 hours. Thus, it appears that patients who died in this very early period had larger, more hemodynamically significant infarctions or had more preexisting myocardial damage and were less able to survive the initial hours until adequate recovery of left ventricular function could occur.
The high "mortality density" within the early hours after reperfusion therapy is in agreement with data from other large-scale studies of patients with myocardial infarction.2-4 The present data are unique, however, in that they very strongly establish a link between early restoration of antegrade coronary arterial blood flow and a reduction of early mortality, thus suggesting that at least a large proportion of the deaths during this period results from a failure of reperfusion to occur. It is also quite clear that earlier reperfusion is associated with an early survival advantage, and these data strongly suggest that future attention be directed toward more reliable means of ensuring rapid reperfusion, even in those patients who do not have pump dysfunction at the time of initial presentation.
